Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Some claims about identity and labeled adverse effects are supported, but many other claims (exercise effects, anxiety/depression worsening, sweating/dehydration/electrolytes, and breastfeeding harm) are not supported by the provided labeling excerpts; overall alignment is limited.
Category Scores
Accurate Statements
Lyrica is also known as pregabalin.
11 DESCRIPTION: 'LYRICA (pregabalin)'
Common side effects of Lyrica include dizziness.
6 ADVERSE REACTIONS and 5.5 Dizziness and Somnolence
Common side effects of Lyrica include drowsiness.
6 ADVERSE REACTIONS and 5.5 Dizziness and Somnolence (somnolence)
Common side effects of Lyrica include weight gain.
6 ADVERSE REACTIONS and 5.8 Weight Gain
Pregabalin is a medication primarily used to treat fibromyalgia.
1 INDICATIONS AND USAGE: 'Management of fibromyalgia'
Unsupported Statements
Pregabalin is a medication primarily used to treat epilepsy.
Provided label evidence does not state a general 'epilepsy' use; it specifies adjunctive therapy for partial-onset seizures.
Lyrica can sometimes exacerbate symptoms of anxiety and depression.
No provided labeling excerpt addresses anxiety/depression symptom worsening.
Regular exercise can help alleviate symptoms of anxiety and depression in individuals taking Lyrica.
No provided labeling excerpt addresses exercise affecting anxiety/depression.
Heavy workouts can lead to increased muscle fatigue.
No provided labeling excerpt addresses exercise causing muscle fatigue.
Increased muscle fatigue may worsen symptoms of fibromyalgia.
No provided labeling excerpt links exercise-induced muscle fatigue to fibromyalgia symptom worsening.
Exercise can cause increased sweating.
No provided labeling excerpt addresses sweating.
Increased sweating may lead to dehydration.
No provided labeling excerpt addresses sweating or dehydration leading to effects on pregabalin.
Dehydration and electrolyte imbalances may affect the body's ability to process pregabalin.
No provided labeling excerpt addresses dehydration/electrolytes affecting pregabalin processing.
A study in healthy individuals found that exercise had no significant effect on the pharmacokinetics of pregabalin.
No provided labeling excerpt includes this study or this conclusion.
A study found that exercise can increase the clearance of pregabalin in individuals with fibromyalgia.
No provided labeling excerpt includes this study or this conclusion.
Contradictions
Important Omissions
Pregabalin seizure effects are described only as adjunctive therapy for partial-onset seizures; the response does not specify partial-onset or adjunctive use when discussing seizure frequency/severity.
Importance:
Moderate
Breastfeeding/lactation risk statements cannot be verified from the provided excerpts because only the '8.2 Lactation' section header is shown without the actual labeled text.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Unsupported claims about exercise/mental health effects and lactation harm may misinform clinical decisions. The labeling excerpts provided do not support these statements, and some key labeling safety areas (e.g., lactation content, contraindications, boxed warnings, dosing/administration) were not available for verification.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Partially Aligned
Primary Issue
Multiple statements (exercise effects, anxiety/depression worsening, sweating/dehydration/electrolytes effects, and breastfeeding harm) are not supported by the provided FDA label excerpts.
Suggested Improvement
Restrict claims to what is explicitly supported by the provided label sections; remove or qualify unsupported exercise and anxiety/depression statements, and omit breastfeeding harm claims unless the provided labeling text for 8.2 Lactation is available and supports the statement.